# Circassia Limited clinical trials: 35 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials with Circassia Limited as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Circassia Limited: 35 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/circassia-limited

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 10, 2016 | NCT02795273 | Efficacy and Safety of Grass-SPIRE Registration Study | Circassia Limited | Phase 2/3 | Withdrawn | Rhinitis, Conjunctivitis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02795273) |
| June 23, 2015 | NCT02478060 | Birch-SPIRE Safety and Efficacy Study | Circassia Limited | Phase 2 | Completed | Rhinitis | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02478060) |
| March 24, 2015 | NCT02396680 | Ragweed-SPIRE Follow-On Study | Circassia Limited | Observational | Completed | Rhinoconjunctivitis, Ragweed Allergy | 249 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02396680) |
| November 17, 2014 | NCT02292875 | ToleroMune Grass Follow on Study | Circassia Limited | Observational | Completed | Rhinoconjunctivitis, Grass Allergy | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02292875) |
| June 11, 2014 | NCT02161107 | Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma | Circassia Limited | Phase 2 | Completed | Seasonal Allergic Rhinitis, Asthma | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02161107) |
| May 29, 2014 | NCT02150343 | Phase II HDM-SPIRE Safety and Efficacy Study | Circassia Limited | Phase 2 | Completed | Rhinoconjunctivitis | 715 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02150343) |
| March 3, 2014 | NCT02075138 | Grass Observational Study | Circassia Limited | Observational | Completed | Grass Allergy, Rhinoconjunctivitis | 109 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02075138) |
| February 13, 2014 | NCT02061709 | Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber | Circassia Limited | Phase 2 | Completed | Seasonal Allergic Rhinitis | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02061709) |
| February 13, 2014 | NCT02061670 | Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma | Circassia Limited | Phase 2 | Completed | Seasonal Allergic Rhinitis, Asthma | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02061670) |
| January 20, 2014 | NCT02040844 | Phase III Cat-PAD Follow-on Study | Circassia Limited | Phase 3 | Completed | Cat Allergy | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02040844) |
| September 24, 2013 | NCT01949441 | ToleroMune House Dust Mite (HDM) Tolerability Study | Circassia Limited | Phase 2 | Completed | Rhinoconjunctivitis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01949441) |
| September 24, 2013 | NCT01949428 | House Dust Mite Observational Study | Circassia Limited | Observational | Completed | Rhinoconjunctivitis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01949428) |
| September 24, 2013 | NCT01949415 | An Optional Investigation of Biomarkers of Efficacy | Circassia Limited | Observational | Completed | Rhinoconjunctivitis | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01949415) |
| August 16, 2013 | NCT01923792 | ToleroMune House Dust Mite Follow on Study | Circassia Limited | Observational | Completed | House Dust Mite Allergy, Rhinoconjunctivitis | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01923792) |
| August 16, 2013 | NCT01923779 | ToleroMune Grass Follow on Study | Circassia Limited | Observational | Completed | Grass Allergy, Rhinoconjunctivitis | 163 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01923779) |
| August 13, 2013 | NCT01921257 | Paediatric Safety Study in Cat-PAD | Circassia Limited | Phase 2 | Completed | Rhinoconjunctivitis | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01921257) |
| December 6, 2012 | NCT01743118 | Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris | Circassia Limited | Phase 1 | Completed | Psoriasis Vulgaris | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01743118) |
| June 15, 2012 | NCT01620762 | Phase III Cat-PAD Study | Circassia Limited | Phase 3 | Completed | Rhinoconjunctivitis | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01620762) |
| May 23, 2012 | NCT01604018 | An Optional Two Year Follow Up Study to Study CP005A | Circassia Limited | Observational | Completed | Cat Allergy, Rhinoconjunctivitis | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01604018) |
| October 7, 2011 | NCT01448603 | ToleroMune Ragweed Follow up Study | Circassia Limited | Observational | Completed | Ragweed Allergy, Rhinoconjunctivitis | 109 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01448603) |
| October 6, 2011 | NCT01447784 | ToleroMune House Dust Mites (HDM) Exposure Chamber Study | Circassia Limited | Phase 2 | Completed | Rhinoconjunctivitis | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01447784) |
| July 20, 2011 | NCT01398137 | Ragweed Observational Study | Circassia Limited | Observational | Completed | Ragweed Allergy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01398137) |
| June 30, 2011 | NCT01385800 | ToleroMune Grass Exposure Unit Study | Circassia Limited | Phase 2 | Completed | Grass Allergy, Rhinoconjunctivitis | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01385800) |
| June 28, 2011 | NCT01383603 | Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis | Circassia Limited | Phase 1 | Completed | Cat Allergy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01383603) |
| June 28, 2011 | NCT01383590 | Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis | Circassia Limited | Phase 1 | Completed | Cat Allergy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01383590) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 17 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 34 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypersensitivity | 8 |
| Rhinitis | 5 |
| Rhinitis, Allergic, Seasonal | 3 |
| Dust Mite Allergy | 2 |
| Asthma | 2 |
| Conjunctivitis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Mediators in the United States](https://specstream.ai/data/businesses/mediators/united-states)
- [Sawmills in the United States](https://specstream.ai/data/businesses/sawmills/united-states)
- [Ambulance services in the United States](https://specstream.ai/data/businesses/ambulance-services/united-states)
- [Contract law firms in the United States](https://specstream.ai/data/businesses/contract-law-firms/united-states)
- [Home cleaning companies in the United States](https://specstream.ai/data/businesses/home-cleaning-companies/united-states)
- [Packing supply stores in the United States](https://specstream.ai/data/businesses/packing-supply-stores/united-states)
